Neuropathologic findings in COVID-19 patients should be correlated with clinical neurologic abnormalities
Journal of Neuropathology & Experimental Neurology · 2023
DOI: 10.1093/jnen/nlac128 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2023. Verfasst von Josef Finsterer. Beteiligte Einrichtung: Neurology & Neurophysiology Center, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19, Nervous System Diseases, Nervous System Malformations. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
To the Editor: With interest, I read the article by Eschbacher et al (1) about the autopsy findings in 72 patients who died from coronavirus disease 2019 (COVID-19). It was found that histologic findings were typical of the patient age demographic, such as neurodegenerative disease and arteriolosclerosis, which a subset of cases demonstrated findings which may be associated with sequelae of critical illness, and that 3 cases showed destructive perivascular lesions with axonal injury (1). Severe, acute, respiratory syndrome coronavirus type 2 (SARS-CoV-2) was detected in none of 50 brains (1). The study is appealing but raises concerns that require further discussion. The main limitation of the study is that the types of clinical neurological manifestations in the 72 COVID-19 patients during life were not provided (1). There is also no mention of cerebral/spinal imaging findings, no electroencephalography results, and no information about cerebrospinal fluid findings in the patients. The spectrum of neurological involvement is broad (2) and autopsy findings may depend heavily on the type of neurological compromise associated with SARS-CoV-2. For example, ischemic stroke may cause different neuropathological changes than encephalitis, encephalopathy, nonconvulsive status epilepticus, etc. A further limitation of the study is that no information about the myelin was provided. In how many of the 72 patients was the myelin investigated and affected? This is of interest as neuro-COVID may manifest not only as acute disseminated encephalomyelitis (ADEM) but also as transverse myelitis, spinal infarct, or as Guillain-Barré syndrome (GBS) (2). In GBS spinal nerve roots may be swollen and there may be demyelination of the nerve roots or axonal loss in the case of an axonal form of GBS. Were any of the patients diagnosed with GBS intra vitam? Another limitation is that no information about the pituitary gland was provided. There is increasing evidence that SARS-CoV-2 infections can be complicated by pituitary apoplexy or hypophysitis (3). Therefore, it is crucial to carefully investigate the pituitary gland in an autopsy study of COVID-19 patients. How many COVID patients included in the study had recovered from the infection? Those who recovered from SARS-CoV-2 and died within 1 year after the infection (n = 24) should be excluded from the study because it is uncertain if their death was related to acute SARS-CoV-2 and because it remains uncertain whether SARS-CoV-2-associated neuropathological abnormalities may still be present after up to 1 year after the infection. Were cerebral arteries and veins systematically macroscopically and microscopically inspected? Neuro-COVID-19 can manifest as venous sinus thrombosis (4). Endothelialitis has been reported as the cause of ischemic stroke in COVID-19 patients (5). Were the cerebral vessels systematically investigated for endothelial dysfunction? Seven patients had a subdural hematoma (SDH) and 5 had subarachnoid bleeding (SAB) on autopsy (1). In how many of these patients were SDH and SAB diagnosed intra vitam and were the causes of SDH or SAB identified? Particularly, how many of these 12 patients had a traumatic brain injury prior to death and in how many of the 5 patients with SAB was an aneurysm detected? Had the 2 patients with diffuse, petechial white matter hemorrhage, undergone cerebral MRI intra vitam and was the condition diagnosed as acute, hemorrhagic, necrotizing encephalitis (AHNE), a subtype of ADEM. AHNE should be considered in these 2 patients as their autopsy findings had an ADEM-like appearance (1). Twenty-three patients obviously had ischemic stroke (“remote infarcts”) (1). However, the cardiovascular risk profile was not provided. We should know how many of these 23 patients had arterial hypertension, atrial fibrillation, diabetes, hyperlipidemia, or were smokers. Before attributing stroke to a SARS-CoV-2 infection, other more plausible causes should be thoroughly ruled out. Overall, the study carries limitations that require re-evaluation and discussion. Clarifying these weaknesses would strengthen the conclusions and could improve the study. Neuropathological findings in COVID-19 may rarely be a direct consequence of CNS infection by the SARS-CoV-2 virus but more commonly sequelae of the immunological response against the virus or consequences of severe pulmonary or systemic illness resulting in multiorgan dysfunction. No funding was received. The author has no duality or conflict of interest to declare.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Neurology & Neurophysiology Center, Vienna, Austria.
ORCID-Profile: Josef Finsterer
Zitieren
APA
Finsterer, J. (2023). Neuropathologic findings in COVID-19 patients should be correlated with clinical neurologic abnormalities. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlac128
Vancouver
Finsterer J. Neuropathologic findings in COVID-19 patients should be correlated with clinical neurologic abnormalities. Journal of Neuropathology & Experimental Neurology. 2023. doi:10.1093/jnen/nlac128
BibTeX
@article{Finsterer2023,
author = {Finsterer, Josef},
title = {Neuropathologic findings in COVID-19 patients should be correlated with clinical neurologic abnormalities},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2023},
doi = {10.1093/jnen/nlac128}
}
EUVIMED